Tuesday, October 1, 2019
Category: Antimicrobial Resistance Mechanisms, Bacterial Infections, Hospital Infections
Dr. Bachmeier presents an up-to-date review of newer-generation antimicrobials designed to be effective against infections with multiple drug-resistant pathogens. He first reviews the different types of extended-spectrum beta-lactamase (ESBL) resistance. He then discusses the significance of Carbapenemase-producing enterobacteriaceae and ESBL producing E coli, Klebsiella pneumonia, and Pseudomonas aeruginosa strains. Such organisms have become increased threats to our patients over the last two decades while new drug approvals have dwindled. Dr. Bachmeier reviews Ceftolozane-tazobactam, Ceftazidime-avibactam and their current indications. He then reviews Meropenem-vaborbactam and its utility in the treatment of Klebsiella pneumonia carbabenemase (KPC) infections. He then discusses imipenem-relebactam and its advantages in the treatment of MDR gram-negative infections. Lastly, he reviews plazomycin, eravacycline, and Cefiderocol.
Stay in touch! Download our app in the iTunes store or the Google Marketplace.
